Compare XELB & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XELB | ADXN |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.1M |
| IPO Year | N/A | N/A |
| Metric | XELB | ADXN |
|---|---|---|
| Price | $1.05 | $7.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 48.2K | 7.9K |
| Earning Date | 11-19-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,980,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | $83.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $6.51 |
| 52 Week High | $7.40 | $12.05 |
| Indicator | XELB | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 42.81 |
| Support Level | $0.91 | $7.65 |
| Resistance Level | $1.02 | $8.49 |
| Average True Range (ATR) | 0.08 | 0.57 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 84.76 | 24.86 |
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.